Ongoing and planned adjuvant trials with trastuzumab

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 11, 2000, Pages 26-32

  Perez, E A ^a   Hortobagyi, G N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; PACLITAXEL; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; GENES, ERBB-2; HUMANS;

EID: 0034474587     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. HER-2/neu (c-erb-B2) gene land protein in breast cancer
2. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
3. Her-2 as a prognostic, predictive, and therapeutic target in breast cancer
4. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor
5. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
6. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
7. Initial report of the SWOG biological correlative study of C-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone
8. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
9. Phase I E1A gene therapy in patients with advanced breast and ovarian cancers
10. HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer
11. Humanization of an anti-p185HER2 antibody for human cancer treatment
12. Radio-labeled antibody targeting of the HER-2/neu oncoprotein
13. Monoclonal antibody to HER-2/neu gene product potentiates cytotoxicity of carboplatin and doxorubicin in human breast tumor cells
14. Ongoing phase II study of intravenous recombinant human anti-p185 HER2 monoclonal antibody 4D5 (MAb 4D5) in patients with stage IV breast cancer overexpressing HER2
15. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/ neu-overexpressing metastatic breast cancer
16. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
17. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial
18. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer
19. Prognostic importance of c-erbB-2 expression in breast cancer
20. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
21. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
22. HER-2/neu as a predictive marker of response to breast cancer therapy
23. Polychemotherapy for early breast cancer: An overview of the randomised trials
24. Tamoxifen for early breast cancer: An overview of the randomized trials
25. Ovarian ablation in early breast cancer: Overview of the randomised trials
26. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer
27. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen non-responsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
28. Combination chemotherapy as an adjuvant treatment in operable breast cancer
29. Early and delayed clinical cardiotoxicity of doxorubicin
30. Risk factors for doxorubicin-induced congestive heart failure
31. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma
32. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
33. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
34. Phase II study of TLC D-99 (liposomal doxorubicin), 5-FU, cyclophosphamide in patients with metastatic breast cancer
35. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial
36. Improved disease-free (DSF) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)
37. Optimal dose and sequence finding study of paclitaxel by 3 H infusion combined with bolus doxorubicin in untreated metastatic breast cancer patients
38. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
39. Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer
40. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: Efficacy and cardiotoxicity considerations
41. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer
42. Phase I/II study of sequential combination of paclitaxel and doxorubicin in the treatment of advanced breast cancer
43. Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer
44. Prospective randomized trial of paclitaxel alone versus 5- fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer
45. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neo-adjuvant therapy in patients with operable breast cancer
46. Role of paclitaxel in adjuvant therapy of operable breast cancer: Preliminary results of a prospective randomized clinical trial
47. A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer
48. Weekly Herceptin + 1 hour Taxol: Phase II study in HER2 overexpressing and non-overexpressing metastatic breast cancer
49. A phase II study of paclitaxel plus carboplatin as first-line chemotherapyl for women with metastatic breast carcinoma